GSK cancer vaccine disappoints in melanoma trial

By Ben Hirschler LONDON (Reuters) – An experimental cancer vaccine from GlaxoSmithKline failed to help melanoma patients in a closely watched late-stage clinical trial, dealing a blow to the high-risk, high-reward project. Britain's biggest drugmaker said on Thursday that it would continue with the Phase III trial of its MAGE-A3 therapeutic vaccine to see if it benefited a subset of patients with a particular genetic signature. …